Lead sponsor
The University of Texas Health Science Center at San Antonio
15 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 6, 2026.
15
Trials led
6
Ongoing
1,445
Total enrollment
6
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Early Phase 1
4
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
7
Not applicable
1
Trials by status
Recruiting
6
Completed
9
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM-Ph 4Completed318
Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset DiabetesHbA1c ≥6.5%Ph 3Recruiting256
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass SurgeryHealthy volunteersEarly Ph 1Recruiting160
Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in GlucosuriaBMI 21-45Ph 4Completed107
Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DMBMI 25-35Ph 4Completed90
Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic PatientsHbA1c 7-10%not applicableCompleted45
Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue TherapyBMI 24-40Ph 4Completed23
Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older AdultsBMI ≥27Ph 4Completed20
Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DMBMI 25-40Early Ph 1Completed4